H.C. Wainwright Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces $22 Price Target

H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and a $22 price target.

Benzinga · 01/07/2020 12:49

H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and a $22 price target.